

Division of Child and Family Health- Newborn Screening Follow-Up Program

## Elevated Fatty Acid: C16-OH 3-hydroxypalmitoylcarnitine

Health Care Professional Fact Sheet

A newborn screening test is a <u>screen</u> and not diagnostic testing. An "abnormal" or "critical" result on a newborn screen indicates the baby may be at a higher risk of having a disorder; however, it does not diagnose the baby with the condition. Follow-up testing is <u>vital</u> to determine if the baby has the disorder indicated. In the event the condition is diagnosed, timely follow-up testing will result in earlier treatment and better outcomes.

**Disorder(s) Indicated:** Long-chain L-3-hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD) and Trifunctional Protein Deficiency (TFP) are fatty acid oxidation disorders that could be identified through the elevation of the fatty acid C16-OH. These disorders are conditions in which the body does not have sufficient enzymes to break down long chain fatty acids due to an inherited enzyme deficiency. Fatty acids are an important energy source for the body. If left untreated, these disorders could cause developmental delays, cardiac and liver issues, coma, or even death. However, if the conditions are detected early and treatment is begun, individuals can have healthy growth and development.

Incidence	Unknown
Analyte Measured	Primary Marker: C16-OH 3-hydroxypalmitoylcarnitine
Allalyte Measured	Secondary Markers*: C16 palmitoylcarnitine, C18:10H 3-hydroxyoleoylcarnitine
	Secondary Warkers : C10 painted yield matter, C10.10113 Hydroxyoled yield matter
	* an abnormal secondary marker paired with an abnormal primary marker will result in
	critical group and require referral and diagnostic testing
Normal Test Results	C16-OH < 0.10 μmol/L
Abnormal Test Results	C16-OH ≥ 0.10 μmol/L to < 0.19 μmol/L
Critical Test Results	C16-OH ≥ 0.19 µmol/L
	(Critical results require immediate evaluation and follow-up)
Signs and Symptoms	When a child has a fatty acid oxidation disorder, you may see symptoms including:
	Poor appetite
Please note: these	Tiredness/Sleeping longer or more often
findings may not be	Vomiting/Diarrhea
present in young infants	Hypoglycemia (low blood sugar)
or in milder forms of the	Behavior changes/irritability
disease	Breathing difficulty
	Seizures
	Symptoms can be triggered or exacerbated by periods of fasting, illness, or infections
Next Steps <i>may</i> include:	Discuss the next steps of evaluation and possible treatment with
	the regional Geneticist
	Provide parental education (see accompanying sheet)
	Clinical Assessment
	Assay: Plasma Acylcarnitines, Urine Organic Acids
Treatment (if indicated)	Restricted diet/supplements (Discuss with the regional Geneticist)
Additional Resources	VDH Newborn Screening <a href="http://vdhlivewell.com/newbornscreening">http://vdhlivewell.com/newbornscreening</a>
	Baby's First Test <u>www.babysfirsttest.org</u>
	American College of Medical Genetics (ACMG) ACT Sheets www.ACMG.net
	Genetics Home Reference <a href="https://ghr.nlm.nih.gov/">https://ghr.nlm.nih.gov/</a>
	Fatty Oxidation Disorder Family Support Group <a href="http://www.fodsupport.org/">http://www.fodsupport.org/</a>

Educational content adapted from www.babysfirsttest.org

